Inhibikase Therapeutics (IKT) Net Cash Flow Growth (1y) (2021 - 2026)
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 47.11% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.60% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -100.75% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 149.49% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -104.22% |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | -527.01% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -527.01% |
| Mar 31, 2026 | -628.86% |
| Dec 31, 2025 | 81.64% |
| Sep 30, 2025 | -1,716.49% |
| Jun 30, 2025 | 486.72% |
| Mar 31, 2025 | 348.84% |
| Dec 31, 2024 | 1,075.70% |
| Sep 30, 2024 | -116.77% |
| Jun 30, 2024 | 135.74% |
| Mar 31, 2024 | -110.77% |
| Dec 31, 2023 | -504.95% |
| Sep 30, 2023 | 149.02% |
| Jun 30, 2023 | 53.36% |
| Mar 31, 2023 | 21.91% |
| Dec 31, 2022 | 134.34% |
| Sep 30, 2022 | -1,227.75% |
| Jun 30, 2022 | -111.82% |
| Mar 31, 2022 | 4.72% |
| Dec 31, 2021 | -129.39% |
| Sep 30, 2021 | -23,845.75% |